Medigen Vaccine Biologics Stock Profit Margin
| 6547 Stock | TWD 38.90 0.25 0.64% |
Medigen Vaccine Biologics fundamentals help investors to digest information that contributes to Medigen Vaccine's financial success or failures. It also enables traders to predict the movement of Medigen Stock. The fundamental analysis module provides a way to measure Medigen Vaccine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medigen Vaccine stock.
Medigen |
Medigen Vaccine Biologics Company Profit Margin Analysis
Medigen Vaccine's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Medigen Vaccine Profit Margin | 0.13 % |
Most of Medigen Vaccine's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medigen Vaccine Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Medigen Vaccine Biologics has a Profit Margin of 0.13%. This is 101.16% lower than that of the Healthcare sector and 100.56% lower than that of the Biotechnology industry. The profit margin for all Taiwan stocks is 110.24% lower than that of the firm.
Medigen Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medigen Vaccine's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medigen Vaccine could also be used in its relative valuation, which is a method of valuing Medigen Vaccine by comparing valuation metrics of similar companies.Medigen Vaccine is currently under evaluation in profit margin category among its peers.
Medigen Fundamentals
| Return On Equity | 0.0662 | |||
| Return On Asset | 0.0209 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 24.78 B | |||
| Shares Outstanding | 327.2 M | |||
| Shares Owned By Insiders | 27.99 % | |||
| Shares Owned By Institutions | 5.13 % | |||
| Price To Earning | 34.63 X | |||
| Price To Book | 4.71 X | |||
| Price To Sales | 10.51 X | |||
| Revenue | 3.28 B | |||
| Gross Profit | 2.31 B | |||
| EBITDA | 1.53 B | |||
| Net Income | 1.41 B | |||
| Cash And Equivalents | 2.12 B | |||
| Cash Per Share | 9.95 X | |||
| Total Debt | 286.54 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 9.72 X | |||
| Book Value Per Share | 17.52 X | |||
| Cash Flow From Operations | 579.89 M | |||
| Earnings Per Share | 0.91 X | |||
| Number Of Employees | 16 | |||
| Beta | 0.89 | |||
| Market Capitalization | 23.36 B | |||
| Total Asset | 5.3 B | |||
| Z Score | 48.6 | |||
| Net Asset | 5.3 B |
About Medigen Vaccine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medigen Vaccine Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medigen Vaccine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medigen Vaccine Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medigen Vaccine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medigen Vaccine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medigen Vaccine will appreciate offsetting losses from the drop in the long position's value.Moving together with Medigen Stock
Moving against Medigen Stock
| 0.93 | 2891 | CTBC Financial Holding | PairCorr |
| 0.88 | 2891B | CTBC Financial Holding | PairCorr |
| 0.83 | 2883 | China Development | PairCorr |
| 0.77 | 4162 | PharmaEngine | PairCorr |
| 0.74 | 2330 | Taiwan Semiconductor | PairCorr |
The ability to find closely correlated positions to Medigen Vaccine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medigen Vaccine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medigen Vaccine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medigen Vaccine Biologics to buy it.
The correlation of Medigen Vaccine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medigen Vaccine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medigen Vaccine Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medigen Vaccine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Medigen Stock Analysis
When running Medigen Vaccine's price analysis, check to measure Medigen Vaccine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Vaccine is operating at the current time. Most of Medigen Vaccine's value examination focuses on studying past and present price action to predict the probability of Medigen Vaccine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Vaccine's price. Additionally, you may evaluate how the addition of Medigen Vaccine to your portfolios can decrease your overall portfolio volatility.